Arrowhead Pharmaceuticals to Present at Upcoming October 2018 Conferences
PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is
scheduled to present at the following upcoming events:
The 14th Annual Meeting of the Oligonucleotide Therapeutics Society –
Seattle, September 30-October 3, 2018
October 1, 9:20 a.m. PDT – Zhen Li, Ph.D., Arrowhead’s senior
vice president of chemistry and non-clinical development, will deliver
an oral presentation titled, “Direct conjugation approaches in RNAi
come of age – Successful delivery outside of hepatocytes”
October 1, 5:00 p.m. PDT – Rui Zhu, Ph.D., Arrowhead’s senior
process chemist, will deliver an oral presentation titled, “Subcutaneous
delivery of an effective RNA interference (RNAi) therapeutic candidate
silencing angiopoietin-like protein 3 for treatment of hyperlipidemia”
October 3, 4:00 p.m. PDT – James Hamilton M.D., MBA, Arrowhead’s
vice president of clinical development, will deliver an invited,
late-breaker oral presentation titled, “Clinical Development of RNAi
Therapeutics for HBV and Alpha-1 Antitrypsin Deficiency”
2018 Cantor Fitzgerald Global Healthcare Conference – New York,
October 1-3, 2018
October 2, 10:55 a.m. EDT – Christopher Anzalone, Ph.D.,
Arrowhead’s president and chief executive officer, will deliver a
corporate presentation
2018 International HBV Meeting – The Molecular Biology of Hepatitis B –
Taormina, Italy, October 3-6, 2018
October 5, 1:00 p.m. CEST – Christine Wooddell, Ph.D.,
Arrowhead’s director of liver targeting, will deliver a poster
presentation titled, “Gene expression analysis during and after RNAi
treatment of chronically HBV infected chimpanzees”
Chardan 2nd Annual Genetic Medicines
Conference – New York, October 9, 2018
October 9, 1:00 p.m. EDT – Bruce Given, M.D., Arrowhead’s chief
operating officer, will participate in a fireside chat
Arrowhead Analyst and Investor R&D Day – New York, October
16, 2018
October 16, 1:00 p.m. EDT – Arrowhead management and external key
opinion leaders will discuss Arrowhead’s emerging pipeline of RNAi
therapeutics
North American Cystic Fibrosis Conference – Denver, October
18-20, 2018
October 18, 11:15 a.m. MDT – Erik Bush, Ph.D., Arrowhead’s
director of extra-hepatic targeting, will deliver a poster presentation
titled, “A novel targeted RNAi molecule (TRiM™) delivery
platform for the therapeutic inhibition of ENaC in cystic fibrosis lung
disease”
A copy of the presentation materials and webcast links, if the
presentation is being webcast, may be accessed on the Events
and Presentations page under the Investors section of the Arrowhead
website.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable
diseases by silencing the genes that cause them. Using a broad portfolio
of RNA chemistries and efficient modes of delivery, Arrowhead therapies
trigger the RNA interference mechanism to induce rapid, deep, and
durable knockdown of target genes. RNA interference, or RNAi, is a
mechanism present in living cells that inhibits the expression of a
specific gene, thereby affecting the production of a specific protein.
Arrowhead’s RNAi-based therapeutics leverage this natural pathway of
gene silencing.
For more information, please visit www.arrowheadpharma.com,
or follow us on Twitter @ArrowheadPharma.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform
Act:
This news release contains forward-looking statements within the
meaning of the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based upon our
current expectations and speak only as of the date hereof. Our actual
results may differ materially and adversely from those expressed in any
forward-looking statements as a result of various factors and
uncertainties, including the safety and efficacy of our product
candidates, the duration and impact of regulatory delays in our clinical
programs, our ability to finance our operations, the future success of
our scientific studies, our ability to successfully develop drug
candidates, the timing for starting and completing clinical trials,
rapid technological change in our markets, and the enforcement of our
intellectual property rights. Our most recent Annual Report on Form 10-K
and subsequent Quarterly Reports on Form 10-Q discuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We assume no obligation to update or
revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
Contacts
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
